Merck & Co., Inc.

MRKNYSE • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
149.45 USD
↗ 0.46 (0.31%)🟢PRE MARKET (AS OF 07:12 AM EDT)
🟢Market: OPEN

Merck & Co., Inc. (MRK) trades at $149.45 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Aug 20, 2026.

Open?$149.25
High?$150.52
Low?$149.02
Prev. Close?$148.99
Volume?13.8K
Avg. Volume?9.7M
VWAP?$149.78
Rel. Volume?0.00x
Bid / Ask
Bid?$149.13 × 100
Ask?$149.80 × 100
Spread?$0.67
Midpoint?$149.47
Valuation & Ratios
Market Cap?367.6B
Shares Out?2.5B
Float?2.4B
Float %?98.1%
P/E Ratio?115.85
P/B Ratio?8.77
EPS?$1.29
Dividend?2.26%
Ex-Dividend?2026-09-15
News
Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Infectious Disease & Vaccines
Employees
75.0K
Market Cap
375.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.merck.com
Listed
1949-04-20
Address
126 EAST LINCOLN AVENUE
RAHWAY, NJ 07065
Phone: 908-740-4000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
91
Momentum?
50
Short Sent.?
78
Piotroski F-Score?2/9Weak
Altman Z-Score?3.95Safe
Confidence?59%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?1.17%Low
Short Interest?28.3M
Days to Cover?3.3
Free Float2.4B
Avg Daily Volume8.7M
Settlement Date2026-07-31
Financial Health
Current Ratio?1.32Adequate
Quick Ratio?1.10Adequate
Cash Ratio?0.25Low
Debt/Equity?1.29Moderate
ValuationRICHLY VALUEDvs 10 peers + S&P 500
Score
44/100
P/E?
Peers
11
S&P
3
115.9PRICEY▾
P/B?
Peers
50
S&P
21
8.77HIGH▾
P/S?
Peers
82
S&P
25
5.52FAIR▾
P/FCF?
Peers
70
S&P
46
22.9FAIR▾
EV/EBITDA?
Peers
40
S&P
10
30.3HIGH▾
EV/Sales?
Peers
82
S&P
26
6.23HIGH▾
Returns & Efficiency
ROE?
Peers
25
S&P
24
7.6%FAIR▾
ROA?
Peers
22
S&P
23
2.4%WEAK▾
Cash Flow & Enterprise
FCF?$16.1B
Enterprise Value?$414.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist